Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.
Ji L, Jiang X, Hao Q, Cheng Z, Wang K, Pang S, Liu M, Guo Y, Chen X, Su X, Ning T, Liu J, Bian F, Li Y, Zhang Z, Song W, Sun J. Ji L, et al. Diabetes Obes Metab. 2023 May;25(5):1229-1240. doi: 10.1111/dom.14971. Epub 2023 Jan 20. Diabetes Obes Metab. 2023. PMID: 36594724 Clinical Trial.
Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.
Ji L, Liu J, Yang J, Li Y, Liang L, Zhu D, Li Q, Ma T, Xu H, Yang Y, Zeng J, Feng B, Qu S, Li Y, Ma L, Lin S, Wang J, Li W, Song W, Li X, Luo Y, Xi S, Lin M, Liu Y, Liang Z. Ji L, et al. Diabetes Obes Metab. 2018 Apr;20(4):1006-1013. doi: 10.1111/dom.13190. Epub 2018 Jan 22. Diabetes Obes Metab. 2018. PMID: 29227571 Clinical Trial.
Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII).
Ji L, Wan H, Wen B, Wang X, Wang J, Bian R, Pang W, Tian J, Wang Y, Bian F, Gao Z, Condoleon A, Feng W, Zhang X, Cui N. Ji L, et al. Diabetes Obes Metab. 2020 May;22(5):838-846. doi: 10.1111/dom.13967. Epub 2020 Feb 18. Diabetes Obes Metab. 2020. PMID: 31944546 Free PMC article. Clinical Trial.
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, Cai C, Deng H, Feng L, Song B, Ma Q, Qian L. Ji L, et al. EClinicalMedicine. 2022 Oct 7;54:101691. doi: 10.1016/j.eclinm.2022.101691. eCollection 2022 Dec. EClinicalMedicine. 2022. PMID: 36247927 Free PMC article.
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Gao L, Cheng Z, Su B, Su X, Song W, Guo Y, Liao L, Chen X, Li J, Tan X, Xu F, Pang S, Wang K, Ye J, Wang Y, Chen L, Sun J, Ji L. Gao L, et al. Among authors: ji l. Diabetes Obes Metab. 2023 Mar;25(3):785-795. doi: 10.1111/dom.14926. Epub 2022 Dec 12. Diabetes Obes Metab. 2023. PMID: 36433709 Clinical Trial.
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.
Ji L, Lu J, Gao L, Yan X, Li J, Cheng Z, Zhang L, Tian J, Li P, Bai J, Xie D, Zhao J, Ding J, Yu Q, Wang T. Ji L, et al. Diabetes Obes Metab. 2023 Dec;25(12):3788-3797. doi: 10.1111/dom.15274. Epub 2023 Sep 19. Diabetes Obes Metab. 2023. PMID: 37724698 Clinical Trial.
5,297 results